RX 108
Alternative Names: RX108Latest Information Update: 28 Sep 2021
At a glance
- Originator Suzhou NeuPharma
- Developer Suzhou NeuPharma; University of Western Sydney
- Class Antineoplastics; Small molecules; Steroids
- Mechanism of Action Sodium-potassium-chloride symporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 28 Aug 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Australia (IV, Infusion)
- 28 Aug 2018 Phase I development is ongoing in Australia (ACTRN12616000008426)